Miller Anestesia

544. DietrichW, Spath P, Zuhlsdorf M, et al: Anaphylactic

reactions to aprotinin reexposure in cardiac surgery:

Relation to antiaprotinin immunoglobulin G and E

antibodies. Anesthesiology 95:64–71, 2001.

545. Kaddoum RN, Chidiac EJ, Zestos MM, et al: An

anaphylactic reaction after primary exposure to an

aprotinin test dose in a child with a severe milk

allergy. J Cardiothorac Vasc Anesth 21:243–244,

2007.

546. Diefenbach C, Abel M, Limpers B, et al: Fatal ana-

phylactic shock after aprotinin reexposure in

cardiac surgery. Anesth Analg 80:830–831, 1995.

547. Beierlein W, Scheule AM, Dietrich W, et al: Forty

years of clinical aprotinin use: A review of 124

hypersensitivity reactions. Ann Thorac Surg

79:741–748, 2005.

548. Dietrich W, Spath P, Ebell A, et al: Prevalence of

anaphylactic reactions to aprotinin: Analysis of two

hundred forty-eight reexposures to aprotinin in

heart operations. JThorac Cardiovasc Surg 113:194–

201, 1997.

549. Levy JH: Safety of aprotinin in heparinized and

nonheparinized patients. J Cardiothorac Vasc

Anesth 18:38S–42S, 2004.

550. Cosgrove DM III, Heric B, Lytle BW, et al: Aprotinin

therapy for reoperative myocardial revasculariza-

tion: A placebo-controlled study. Ann Thorac Surg

54:1031–1036, 1992.

551. Smith PK, Datta SK, Muhlbaier LH, et al: Cost

analysis of aprotinin for coronary artery bypass

patients: Analysis of the randomized trials. Ann

Thorac Surg 77:635–642, 2004.

552. Mora Mangano CT, Neville MJ, Hsu PH, et al: Apro-

tinin, blood loss, and renal dysfunction in deep

hypothermic circulatory arrest. Circulation

104:I276–I281, 2001.

553. Royston D, Levy JH, Fitch J, et al: Full-dose aproti-

nin use in coronary artery bypass graft surgery: An

analysis of perioperative pharmacotherapy and

patient outcomes. Anesth Analg 103:1082–1088,

2006.

554. Mangano DT, Tudor IC, Dietzel C: The risk associa-

ted with aprotinin in cardiac surgery. N Engl J Med

354:353–365, 2006.

555. Hoffman M: A cell-based model of coagulation and

the role of factor VIIa. Blood Rev 17(Suppl 1)S1–S5,

2003.

556. Raivio P, Suojaranta-Ylinen R, Kuitunen AH:

Recombinant factor VIIa in the treatment of posto-

perative hemorrhage after cardiac surgery. Ann

Thorac Surg 80:66–71, 2005.

557. Filsoufi F, Castillo JG, Rahmanian PB, et al: Effective

management of refractory postcardiotomy bleeding

with the use of recombinant activated factor VII.

Ann Thorac Surg 82:1779–1783, 2006.

558. Bishop CV, Renwick WE, Hogan C, et al: Recombi-

nant activated factor VII: Treating postoperative

hemorrhage in cardiac surgery. Ann Thorac Surg

81:875–879, 2006.

559. Warren O, Mandal K, Hadjianastassiou V, et al:

Recombinant activatedfactor VII in cardiacsurgery:

A systematic review. Ann Thorac Surg 83:707–714,

2007.

560. von Heymann C, Redlich U, Jain U, et al: Recombi-

nant activated factor VII for refractory bleeding

after cardiac surgery—a retrospective analysis of

safety and efficacy. Crit Care Med 33:2241–2246,

2005.

561. Karkouti K, Yau TM, Riazi S, et al: Determinants of

complications with recombinant factor VIIa for

refractory blood loss in cardiac surgery. Can J

Anaesth 53:802–809, 2006.

562. Tobias JD, Simsic JM, Weinstein S, et al: Recombi-

nant factor VIIa to control excessive bleeding

following surgery for congenital heart disease in

pediatric patients. J Intensive Care Med 19:270–273,

2004.

563. Romagnoli S, Bevilacqua S, Gelsomino S, et al:

Small-dose recombinant activated factor VII

(NovoSeven) in cardiac surgery. Anesth Analg

102:1320–1326, 2006.

564. Diprose P, Herbertson MJ, O’Shaughnessy D, et al:

Activated recombinant factor VII after cardiopul-

monary bypass reduces allogeneic transfusion in

complex non-coronary cardiac surgery: Randomi-

zed double-blind placebo-controlled pilot study. Br

J Anaesth 95:596–602, 2005.

565. Ekert H, Brizard C, Eyers R, et al: Elective adminis-

tration in infants of low-dose recombinant activa-

ted factor VII (rFVIIa) in cardiopulmonary bypass

surgery for congenital heart disease does not

shorten time to chest closure or reduce blood loss

and need for transfusions: A randomized, double-

blind, parallel group, placebo-controlled study of

rFVIIa and standard haemostatic replacement

therapy versus standard haemostatic replacement

therapy. Blood Coagul Fibrinolysis 17:389–395,

2006.

566. Spiess BD: Blood conservation: Why bother? J Car-

diothorac Vasc Anesth 18:1S–5S, 2004.

567. Green JA: Blood conservation in cardiac surgery:

The Virginia Commonwealth University (VCU)

experience. J Cardiothorac Vasc Anesth 18:18S–23S,

2004.

568. Helm RE, Rosengart TK, Gomez M, et al: Compre-

hensive multimodality blood conservation: 100

consecutive CABG operations without transfusion.

Ann Thorac Surg 65:125–136, 1998.

569. Spiess BD, Gillies BS, Chandler W, et al: Changes in

transfusion therapy and reexploration rate after ins-

titution of a blood management program in cardiac

surgical patients. J Cardiothorac Vasc Anesth

9:168–173, 1995.

570. Royston D, von Kier S: Reduced haemostatic factor

transfusion using heparinase-modified thrombelas-

tography during cardiopulmonary bypass. Br J

Anaesth 86:575–578, 2001.

571. Mangano DT, Siliciano D, Hollenberg M, et al:

Postoperative myocardial ischemia: Therapeutic

trials using intensive analgesia following surgery.

The Study of Perioperative Ischemia (SPI) Research

Group. Anesthesiology 76:342–353, 1992.

572. Brown DL, Carpenter RL: Perioperative analgesia:

A review of risks and benefits. J Cardiothorac

Anesth 4:368–383, 1990.

573. Weissman C: Pulmonary function after cardiac and

thoracic surgery. Anesth Analg 88:1272–1279,

1999.

574. Liu SS, Block BM, Wu CL: Effects of perioperative

central neuraxial analgesia on outcome after coro-

nary artery bypass surgery: A meta-analysis. Anes-

thesiology 101:153–161, 2004.

575. Ronald A, Abdulaziz KA, Day TG, et al: In patients

undergoing cardiac surgery, thoracic epidural anal-

gesia combined with general anaesthesia results in

faster recovery and fewer complications but does

not affect length of hospital stay. Interact Cardio-

vasc Thorac Surg 5:207–216, 2006.

576. Olivier JF, Bracco D, Nguyen P, et al: A novel appro-

ach for pain management in cardiac surgery via

median sternotomy: bilateral single-shot paraverte-

bral blocks. Heart Surg Forum 10:E357–E362,

2007.

577. Dowling R, Thielmeier K, Ghaly A, et al: Improved

pain control after cardiac surgery: Results of a ran-

domized, double-blind, clinical trial. J Thorac Car-

diovasc Surg 126:1271–1278, 2003.

578. Practice guidelines for acute pain management in

the perioperative setting: An updated report by the

American Society of Anesthesiologists Task Force

on Acute Pain Management. Anesthesiology 100,

1573-1581, 2004.

579. Joshi GP, Gertler R, Fricker R: Cardiovascular

thromboembolic adverse effects associated with

cyclooxygenase-2 selective inhibitors and nonselec-

tive antiinflammatory drugs. Anesth Analg

105:1793–1804, 2007.

580. Nussmeier NA, Whelton AA, Brown MT, et al:

Complications of the COX-2 inhibitors parecoxib

and valdecoxib after cardiac surgery. N Engl J Med

352:1081–1091, 2005.

581. Schwann NM, Chaney MA: No pain, much gain? J

Thorac Cardiovasc Surg 126:1261–1264, 2003.

Anestesia para los procedimientos de cirugía cardíaca

1741

Sección IV

Anestesia por subespecialidades en el adulto